Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYH2053 injection in primary hypercholesterolemia and mixed dyslipidemia (China, phase 3)
CTR20260549Phase 3Active
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and combined dyslipidaemia comparing SYH2053 injection with Placebo injection (2 arms). Primary endpoint: Percent change in LDL-C from baseline at Day 330. Started Mar 2026; status: active.
02
Drugs
SYH2053
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20260549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260549.